• InvestorsInvestors
  • PatientsPatients
  • PressPress
  • Chercher dans le siteChercher dans le site

Select your language

  • FR
Alzprotect Alzprotect
  • Company
    • About the Company
    • Team
    • Partners
    • Careers
  • Expertise
    • Therapeutic Strategy
    • Research & Development
    • Publication
  • Pipeline
  • News
  • Contact
  • InvestorsInvestors
  • PatientsPatients
  • PressPress
  • Chercher dans le siteChercher dans le site

Select your language

  • FR

News

Laboeatory

Alzprotect announces the extension of Phase 2a clinical trial for the treatment of progressive supranuclear palsy (PSP)

Lille (France), 16 February 2023 – Alzprotect, the French biopharmaceutical company, announces the extension of its Phase 2a clinical trials of its drug candidate for Progressive Supranuclear Palsy (PSP), a neurodegenerative disease similar to Alzheimer's disease, which severely impacts balance, eye movements, cognition and, in the more advanced stages of the disease, the ability to swallow. The initial C04 study (a randomised, blinded study comparing two doses of AZP2006 to placebo) showed posi...

Read more …

Alzprotect announces the completion of clinical trial phase 2a for the treatment of Progressive Supranuclear Palsy (PSP)

Lille (France), 20 September 2022 – On the eve of world Alzheimer’s day, Alzprotect, a biopharmaceutical company developing treatments for neurodegenerative diseases, announces the completion of the phase 2a clinical trial evaluating its platform asset, AZP2006 (“EZEPROGIND”) in Progressive Supranuclear Palsy (PSP), a rare neurodegenerative disease, sharing key features with Alzheimer’s disease, and which seriously impacts balance, eye movement, cognition, and in the latter stage of the disease,...

Read more …

Alzprotect Awarded a Grant from The Michael J. Fox Foundation to Advance Small Molecule Parkinson’s Disease Program

Lille, France – June 1st 2022 – Alzprotect, a French biopharmaceutical company involved in the development of new therapeutic solutions in the neurodegenerative diseases area, today announced it has been awarded a USD $338,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop the first-in-class brain penetrant small molecule targeting Progranulin (PGRN). This grant will further expand Alzprotect’s research efforts to develop AZP2006 (INN Ezeprogind) into a new t...

Read more …

Alzprotect announces the appointment of Dr Susanna Del Signore as Chief Medical Officer

France, Lille - 5 th April 2022 - Alzprotect, a French biopharmaceutical company specialised in the development of new therapeutic solutions for the treatment of neurodegenerative diseases, in particular Alzheimer's disease, appoints Dr Susanna Del Signore as Chief Medical Officer (CMO). Dr Susanna Del Signore has over 20 years of experience in research and development (R&D) in the pharmaceutical industry, particularly in the field of neurology. She has been a project leader, attaining the posit...

Read more …

Alzprotect Completes Phase 2a Clinical Trial Enrollment for AZP2006 in Progressive Supranuclear Palsy (PSP)

Lille (France), January 20th, 2022 – ALZPROTECT , a biopharmaceutical company developing treatments for neurodegenerative diseases, today announced it has completed patient enrollment for the Company’s phase 2a clinical trial evaluating its platform asset, AZP2006 (“EZEPROGIND”) in Progressive Supranuclear Palsy (PSP), a rare neurodegenerative disorder which seriously impacts walking, balance, eye movement, and in the latter stage of the disease, the ability to swallow. This PSP trial, which is...

Read more …

Alzprotect strengthens its Board of Directors with the arrival of Dr. John Tchelingerian

Lille (France), June 22nd, 2021 - ALZPROTECT, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease, announced today that Dr. John Tchelingerian has joined the Board of Directors of Alzprotect. Alzprotect is financed by the Xerys Funds. Dr John Tchelingerian is a serial entrepreneur in life sciences. As a veteran of the industry, he co-founded and/or lead several biotech companies as CEO or Chairman & CEO. He raised a total of over €200 million...

Read more …

Alzprotect and the Rothschild Foundation Hospital announce the signing of a collaboration in a phase 2 clinical trial for the treatment of Progressive Supranuclear Palsy

Lille (France), May 11th - Alzprotect, biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases, and the Adolphe de Rothschild Foundation Hospital announced today the signing of a collaboration agreement. This first materializes with the opening in Paris, within the Rothschild Foundation Hospital of the 3rd clinical center, as part of the phase 2a trial aimed at evaluating the safety of the main drug candidate of the company, EZEPROGIND (AZP2006) for the treatmen...

Read more …

Alzprotect Establishes US Subsidiary

Lille (France), April 8th, 2021 – Alzprotect , a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today today hat it has established its US based subsidiary, Alzprotect US Inc . in Boston, Massachusetts, in line with its international development strategy. This new subsidiary of Alzprotect is situated in Boston. The world’s ten largest biopharma companies have a presence in Massachusetts, making it an ideal location for scientific and technologi...

Read more …

Alzprotect to present at the 14th Annual European Life Sciences CEO Forum

Lille (France), March 7th, 2021 – Alzprotect , a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases is pleased to announce the company will present virtually at the 14th Annual European Life Sciences CEO Forum that will take place from the 10th to the 12th of March 2021, aspart of the Digital Sachs Spring Life Sciences Week. Philippe Verwaerde, Chief Executive Officer of Alzprotect will provide an overview of the development program of the company’s drug Ez...

Read more …

Page 1 of 2

  • 1
  • 2
  • Alzprotect
  • Expertise
  • AZP2006
  • News
  • Investisseurs
  • Patients
  • Press

Alzprotect

85 Rue Nelson Mandela
59120 Loos
France
Tel. +33 972 649 757

Contact

  • Conditions générales d'utilisation
  • Confidentialité

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.

Ok Decline
More information